Codon Devices Achieves Milestone in Collaboration with Agrivida in Novel Protein Engineering for Biofuels

Friday, May 2nd, 2008
Original source of this article:
View this article at external source

Codon Devices Achieves Milestone in Collaboration with Agrivida in Novel Protein Engineering for Biofuels

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Codon Devices, Inc., the Constructive Biologyâ„¢ Company, announced today that it has achieved the first development milestone in its collaboration with Agrivida, Inc.

During the first phase of the collaboration, scientists successfully designed and engineered novel protein switches. The “on/off” switch can be used to activate an enzyme expressed in an inactive form. The successful effort to further develop Agrivida’s GreenGenesTM technology highlights the computational modeling and protein engineering components of Codon Devices’ BioLogic™ Engineering.

Agrivida, an agricultural biotechnology company, is developing plant traits that optimize the production of ethanol. Under the agreement, Codon Devices utilizes its BioLOGIC™ Engineering Platform to develop enzymes optimized for Agrivida’s proprietary biofuel production technology. The agreement provides for Codon Devices to receive performance-based payments and royalties. The collaboration’s objective is to develop and express optimized enzymes in plants that enable a controllable degradation process.

“We believe this is the first time that a protein has been regulated using a distinct thermally activated protein element,” stated Brian M. Baynes, Ph.D., Codon Devices’ founder and President. “This work highlights the strength and creativity of these scientific teams.”

“This is indeed an impressive achievement, and we have had great success working with the Codon Devices team,” noted R. Michael Raab, Ph.D., founder and Chief Executive Officer of Agrivida, Inc. “This accomplishment is accelerating our research as we continue our development of plant traits and technology for the production of biofuels. The development of an effective protein switch has broad implications for the use of optimized proteins across a number plant species, as well as a variety of industries, including bioenergy.”

An integral component of the BioLOGIC Engineering Platform is Codon Devices’ BioFAB™ Production Platform, which produces high quality synthetic genes at a lower cost and quicker turn around time than ever before available.

About Codon Devices

Codon Devices, Inc., based in Cambridge, MA, is a privately-held biotechnology company focused on enabling commercial applications of synthetic biology. Codon Devices’ proprietary synthesis and design technologies improve the productivity of its industrial, pharmaceutical and academic customers in a paradigm shift to what the Company terms Constructive Biologyâ„¢. The Company’s focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered proteins, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and biorefineries for the production of industrial chemicals and biofuels. More information about Codon Devices is available at


Yates Public Relations
Kathryn Morris, 845-635-9828